Patient Preferences and Priorities for the Design of an AKI Prevention Trial: Findings from a Consensus Workshop.
Meghan J ElliottKirsten M FiestShannan LoveDale BirdsellMaureena LothHeather DumkaBenny RanaNusrat S ShommuEleanor BenterudSarah GilDilaram AcharyaTyrone G HarrisonNeesh PannuMatthew Thomas JamesPublished in: Kidney360 (2024)
Findings from our workshop will directly inform development of a clinical trial protocol of cilastatin for nephrotoxic AKI prevention and can assist others in patient-centered approaches to AKI trial design.